Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Federal judge upholds Hawaii's new climate change tax on cruise passengers - 2Rediscovering Imagination in Adulthood: Individual Creative Excursions
- 3Benihana is 60 years old. Gen Z is lining up.
- 4From Exemplary to Current: Famous Rings Available
- 5Hamas delegation meets Egypt’s spy chief amid mutual ceasefire violation claims
- Tech for Wellbeing: Applications and Devices for a Better You
- Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- Conquering Social Generalizations: Individual Accounts of Strengthening
- How did birds survive while dinosaurs went extinct?
- 5 Movies That Leaving an Imprint with Inventive Innovation
- Strengthening through Wellness: Individual Preparation Achievement
- Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- The Best Internet based Courses for Expertise Improvement
